CCR2 INHIBITOR CCX140 EFFECTIVE IN PHASE 2 CLINICAL TRIAL IN DIABETIC NEPHROPATHY

被引：0
|
作者：
de Zeeuw, Dick [1 ]
Henkel, Elena [2 ]
Psottova, Jana [3 ]
Paragh, Gyorgy [4 ]
Mehling, Heidrun [5 ]
Hasslacher, Christopher [6 ]
Potarca, Antonia [7 ]
Bekker, Pirow [8 ]
Schall, Thomas J. [9 ]
机构：
[1] Univ Med Ctr Groningen, Clin Pharm & Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Tech Univ Dresden, Diabet, D-01062 Dresden, Germany
[3] Diainmed, Diabet, Prague, Czech Republic
[4] Univ Debrecen, Diabet, Debrecen, Hungary
[5] Free Univ Berlin, Diabet, Berlin, Germany
[6] Heidelberg Univ, Diabet, Heidelberg, Germany
[7] ChemoCentryx, Clin Operat, Mountain View, CA USA
[8] ChemoCentryx, Med & Clin Affairs, Mountain View, CA USA
[9] ChemoCentryx, R&D, Mountain View, CA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2015年 / 30卷
关键词：
D O I：
10.1093/ndt/gfv195.1
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP457
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial
    Vergunst, Clarissa E.
    Gerlag, Danielle M.
    Lopatinskaya, Luba
    Klareskog, L.
    Smith, M. D.
    van den Bosch, F.
    Dinant, Huib J.
    Lee, Yih
    Wyant, Timothy
    Jacobson, Eric W.
    Baeten, Dominique
    Tak, Paul P.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (07): : 1931 - 1939
  • [42] A potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2/CCR5) inhibitor reduces retinal vascular leakage in an animal model
    Finny Monickaraj
    Sreenivasa R. Oruganti
    Paul McGuire
    Arup Das
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259 : 93 - 100
  • [43] DESIGN OF A PHASE 3 CLINICAL TRIAL IN DIABETIC NEPHROPATHY (DN) WITH PYRIDORIN
    Dwyer, J. P.
    Umanath, K.
    Fox, J. W.
    Peterson, R.
    Broome, B. R.
    Sika, M.
    Lewis, J. B.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 65 (04) : A32 - A32
  • [44] Blockade of CCL2/CCR2 Signalling Ameliorates Diabetic Nephropathyin db/db Mice
    Lee, Eun Young
    Seok, Su Jin
    Lee, Eun Soo
    Lee, Ji-Hye
    Kim, Hong Min
    Kim, Yeo Joo
    Chen, Sheldon
    Chung, Choon Hee
    DIABETES, 2013, 62 : A132 - A132
  • [45] A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206)
    Williams, ME
    Bolton, WK
    Degenhardt, TP
    Schotzinger, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 7A - 7A
  • [46] A potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2/CCR5) inhibitor reduces retinal vascular leakage in an animal model
    Monickaraj, Finny
    Oruganti, Sreenivasa R.
    McGuire, Paul
    Das, Arup
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (01) : 93 - 100
  • [47] CCR2 inhibition improves renal function in diabetic BTBR ob/ob Mice
    Sullivan, T. J.
    Miao, Z.
    Berahovich, R.
    Zhao, B. N.
    Ertl, L.
    Baumgart, T.
    Krasinski, A.
    Dang, T.
    Miao, S.
    Powers, J. P.
    Jaen, J. C.
    Schall, T. J.
    DIABETOLOGIA, 2012, 55 : S19 - S19
  • [48] CCR2 inhibitor strengthens the adiponectin effects against myocardial injury after infarction
    Zheng, Yue
    Gao, Wenqing
    Qi, Bingcai
    Zhang, Ruiying
    Ning, Meng
    Hu, Xiaomin
    Li, Tong
    FASEB JOURNAL, 2023, 37 (08):
  • [49] Inhibition of CCR2 potentiates checkpoint inhibitor immunotherapy in murine model of pancreatic cancer
    Janson, Christine
    Jung, Heiyoun
    Ertl, Linda
    Liu, Shirley
    Dang, Ton
    Zeng, Yibin
    Krasinski, Antoni
    McMahon, Jeff
    Zhang, Penglie
    Charo, Israel
    Singh, Rajinder
    Schall, Thomas J.
    CANCER RESEARCH, 2017, 77
  • [50] CCR2 Inhibition Improves Renal Function in Diabetic BKS db/db Mice
    Sullivan, Timothy J.
    Miao, Zhenhua
    Zhao, Bin N.
    Berahovich, Robert D.
    Powers, Jay P.
    Ertl, Linda
    Jaen, Juan C.
    Schall, Thomas J.
    DIABETES, 2012, 61 : A133 - A133
12345